line
line
line
Poster Session
line
line
line
line

2017 BioMAN Summit

Agenda Day 2 | November 15, 2017

line
7:45 AM – 8:30 AM Breakfast
line
Introduction
line
8:30 AM – 8:35 AM Stacy L. Springs
Executive Director, BioMAN & CAACB; Senior Director of Programs, Center for Biomedical Innovation, Massachusetts Institute of Technology; Associate Institute Director, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
view bio
line
Opening Remarks
line
8:35 AM – 8:45 AM Jennifer Griffin
Vice President, Industry Programs and Relations, Massachusetts Life Sciences Center
view bio
line
Session 3: Regulations and Manufacturing Practices to Ensure Product Safety
line
  Session Chair: Stacy Springs CBI, MIT
line
8:50 AM – 9:40 AM Regulatory and Scientific Considerations to Developing Cell and Gene Therapies - A Perspective from the European Medicines Agency
Veronika Jekerle
Quality Specialist and ATMP Topic Lead for Quality, Specialised Scientific Disciplines Department, European Medicines Agency
view bio | view abstract
line
9:40 AM – 10:15 AM Making Cell Therapy Process Changes: Why, How and When
Gregory Russotti
Vice President, Cell Therapy Development and Operations, Celgene
view bio | view abstract
line
10:15 AM – 10:35 AM Refreshment Break
line
10:35 AM – 11:05 AM Managing Challenges to Supply Autologous Gene Therapies
Jeff Kennedy
Process Manager, Cell and Gene Therapy Validation and Lifecycle Management, GlaxoSmithKline
view bio | view abstract
line
11:05 AM – 11:35 AM Adventitious Agent Control Strategy Considerations
Nigel Pheasey
Principal Scientist, Process Development, Amgen
view bio | view abstract
line
11:35 AM – 12:05 PM The CAACB Virus Contamination in Biomanufacturing Project - Practical Lessons for Current and Emerging Biotherapeutic Products
James Leung
Senior Research Fellow, Center for Biomedical Innovation, Massachusetts Institute of Technology
view bio | view abstract
line
12:05 PM – 1:05 PM Lunch
line
Academic Poster Awards
line
1:05 PM – 1:20 PM Presented by:
John Frenz, President, CAASS
view bio

Stacy L. Springs

Executive Director, BioMAN & CAACB; Senior Director of Programs, Center for Biomedical Innovation, Massachusetts Institute of Technology; Associate Institute Director, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
view bio
line
Session 4: Technologies and Approaches to Enable Commercialization
line
  Session Chair: James C. Leung CBI, MIT
line
1:25 PM – 1:55 PM Development Perspectives in Advancing Pluripotent Stem Cell Therapeutics
Robert Deans
Chief Technology Officer, BlueRock Therapeutics
view bio | view abstract
line
1:55 PM – 2:25 PM Semma Therapeutics – Developing Disruptive Therapies to Cure Insulin-Dependent Diabetes
Austin Thiel
Senior Principal Scientist, Semma Therapeutics
view bio | view abstract
line
2:25 PM – 2:55 PM Analytical Challenges for Characterization of a Complex Allogeneic CAR T Product
Debra Meyer
Associate Research Fellow, Pfizer
view bio | view abstract
line
2:55 PM – 3:15 PM Refreshment Break
line
3:15 PM – 3:45 PM Single T-cell Functional Response Biomarkers to Accelerate Decisions in CAR-T and Checkpoint Based Cancer Immunotherapies
Jon Chen
Single-cell Evangelist, IsoPlexis
view bio | view abstract
line
3:45 PM – 4:15 PM Needles in the Haystack: Label-free, Biophysical Attributes Enabling Cell Therapy
Krystyn Van Vliet
Associate Provost; Professor, Departments of Materials Science and Engineering and Biological Engineering, Massachusetts Institute of Technology
view bio | view abstract
line
4:15 PM – 4:45 PM Distributed CAR-T Manufacturing to Maximize Market
David O'Dowd
Associate Director, Draper
view bio | view abstract
line
4:45 PM – 5:15 PM Challenges in Cell Therapy Manufacturing are Opportunities for Industrializing Production Systems
Julie Murrell
Head of Cell Therapy Manufacturing, MilliporeSigma
view bio | view abstract
line
Closing Remarks
line
5:15 PM – 5:30 PM Stacy L. Springs
Executive Director, BioMAN & CAACB; Senior Director of Programs, Center for Biomedical Innovation, Massachusetts Institute of Technology; Associate Institute Director, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
view bio
line
bottom line
MIT CBI BioMAN